Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Cardiol. doi: /nrcardio

Published byJúlio Espírito Santo Belém Modified over 5 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Cardiol. doi: /nrcardio"— Presentation transcript:

1 Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.131
Figure 4 Possible combinations of classes of antianginal drugs according to different comorbidities Figure 4 | Possible combinations of classes of antianginal drugs according to different comorbidities. BB, β-blockers; DHP, dihydropyridine calcium-channel blockers; DILT, diltiazem; HR, heart rate; IVAB, ivabradine; NIC, nicorandil; NITR, nitrates; RAN, ranolazine; TRIM, trimetazidine; VER, verapamil. Ferrari, R. et al. (2017) A ‘diamond’ approach to personalized treatment of angina Nat. Rev. Cardiol. doi: /nrcardio

Download ppt "Nat. Rev. Cardiol. doi: /nrcardio"

Similar presentations

The Late Sodium Current in the cardiac myocite: How viable as a new therapeutic target in angina? SPONSORED SATELLITE SESSION Dr Stephen Holmberg Lead.

The Late Sodium Current in the cardiac myocite: How viable as a new therapeutic target in angina? SPONSORED SATELLITE SESSION Dr Stephen Holmberg Lead.
How do we further reduce angina in patients already treated with a hemodynamic agent? Benefits of adding a metabolic agent to other antianginal drugs (

How do we further reduce angina in patients already treated with a hemodynamic agent? Benefits of adding a metabolic agent to other antianginal drugs (
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.

European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Benefits of adding a energetic agent to  -blockers to achieve optimal reduction of angina. Review of the main studies.

Benefits of adding a energetic agent to  -blockers to achieve optimal reduction of angina. Review of the main studies.
Antianginal Drugs Learning outcomes Recognize variables contributing to a balanced myocardial supply versus demand Expand on the drugs used to alleviate.

Antianginal Drugs Learning outcomes Recognize variables contributing to a balanced myocardial supply versus demand Expand on the drugs used to alleviate.
Clinical Management of Chronic Stable Angina. Anti-ischemic strategies in stable CAD Medical therapyPCICABG Initial therapy Recurrent ischemia TMREECPSCS.

Clinical Management of Chronic Stable Angina. Anti-ischemic strategies in stable CAD Medical therapyPCICABG Initial therapy Recurrent ischemia TMREECPSCS.
Algorithm for the treatment of atrial fibrillation (AF) and atrial flutter. (BB, β-blocker; CCB, calcium channel blocker [i.e., verapamil or diltiazem];

Algorithm for the treatment of atrial fibrillation (AF) and atrial flutter. (BB, β-blocker; CCB, calcium channel blocker [i.e., verapamil or diltiazem];
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Formative Test.

Formative Test.
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Lung and pleural ultrasonography

Figure 1 Lung and pleural ultrasonography
Figure 2 Different manifestations of myocardial ischaemia

Figure 2 Different manifestations of myocardial ischaemia
Creatinine clearance (mL/min) n All-cause mortality (%)

Creatinine clearance (mL/min) n All-cause mortality (%)
Figure 5 BMI and cardiorespiratory fitness levels

Figure 5 BMI and cardiorespiratory fitness levels
Figure 4 BMI and mortality in patients with heart failure

Figure 4 BMI and mortality in patients with heart failure
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Energy supply–demand matching in health and heart failure

Figure 1 Energy supply–demand matching in health and heart failure
Figure 1 Mechanisms of metastatic growth in the heart

Figure 1 Mechanisms of metastatic growth in the heart

Similar presentations

Ads by Google